Philomena M. Colucci

Hematology

18947 John J Williams Hwy
Rehoboth Beach, DE 19971

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Journal: Lancet (London, England)

Published: March 18, 2026

Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement.

Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement.

Journal: NEJM evidence

Published: August 26, 2025

Identification and Confirmation of Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement and Characterization of Treatment Patterns and Outcomes in a Real-World Setting: A US Retrospective Chart Review.

Identification and Confirmation of Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement and Characterization of Treatment Patterns and Outcomes in a Real-World Setting: A US Retrospective Chart Review.

Journal: Acta haematologica

Published: January 17, 2025

Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group.

Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group.

Journal: Leukemia

Published: November 02, 2022

Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study.

Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: October 08, 2021

Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study.

Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 16, 2021

Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study.

Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study.

Journal: Haematologica

Published: April 21, 2021

Real-World Dosing Patterns of Ruxolitinib in Patients With Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea.

Real-World Dosing Patterns of Ruxolitinib in Patients With Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea.

Journal: Clinical lymphoma, myeloma & leukemia

Published: March 11, 2021

Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Essential Thrombocythemia Enrolled in the MOST Study.

Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Essential Thrombocythemia Enrolled in the MOST Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: December 15, 2020

Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States.

Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States.

Journal: Annals of hematology

Published: April 13, 2020

Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study.

Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 02, 2019

Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study.

Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: April 09, 2019

Showing 1-12 of 15

Last Updated: 09/26/2026